Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed as "Buy" by Truist Financial

Key Points

• Truist Financial reaffirmed its “Buy” rating on Biogen and raised its price target from $235 to $260, implying about 3.4% upside from the stock’s $251.46 trading price.
• Analyst sentiment remains broadly positive: Biogen has a consensus “Moderate Buy” rating and an average price target of $248, while Argus upgraded the stock to “Buy” and other firms raised their targets.
• Biogen beat quarterly expectations with adjusted EPS of $2.62 and revenue of $2.80 billion, up 10.6% year over year, though it posted a $20.6 million GAAP loss driven largely by acquisition-related expenses.

Biogen (NASDAQ:BIIB - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Truist Financial in a research note issued to investors on Thursday, Benzinga reports. They currently have a $260.00 target price on the biotechnology company's stock, up from their prior target price of $235.00. Truist Financial's target price points to a potential upside of 3.40% from the company's current price.

Other equities research analysts have also issued research reports about the stock. Argus raised shares of Biogen from a "hold" rating to a "buy" rating and set a $280.00 price objective for the company in a research report on Thursday. HC Wainwright upped their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Weiss Ratings upgraded Biogen from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, September 24th. Wall Street Zen cut Biogen from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $300.00 target price on shares of Biogen in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Biogen presently has a consensus rating of "Moderate Buy" and a consensus target price of $248.00.

Biogen Stock Up 3.0%

Shares of BIIB traded up $7.41 on Thursday, hitting $251.46. 202,122 shares of the stock traded hands, compared to its average volume of 1,211,260. Biogen has a one year low of $138.00 and a one year high of $258.78. The company has a market capitalization of $37.15 billion, a PE ratio of 44.60, a P/E/G ratio of 2.99 and a beta of 0.09. The business has a 50 day simple moving average of $225.73 and a 200 day simple moving average of $200.39. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same period last year, the business posted $4.81 EPS. The company's revenue was up 10.6% compared to the same quarter last year. As a group, equities analysts forecast that Biogen will post 12.29 earnings per share for the current fiscal year.

Institutional Trading of Biogen

A number of institutional investors have recently modified their holdings of BIIB. Probity Advisors Inc. lifted its stake in shares of Biogen by 3.6% during the third quarter. Probity Advisors Inc. now owns 1,183 shares of the biotechnology company's stock worth $267,000 after buying an additional 41 shares during the period. Forum Financial Management LP increased its position in shares of Biogen by 2.4% in the 3rd quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company's stock valued at $437,000 after acquiring an additional 46 shares during the period. Integrated Advisors Network LLC increased its position in shares of Biogen by 3.5% in the 3rd quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company's stock valued at $317,000 after acquiring an additional 48 shares during the period. Wedbush Securities Inc. raised its stake in Biogen by 5.1% in the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company's stock worth $251,000 after acquiring an additional 56 shares during the last quarter. Finally, Meeder Advisory Services Inc. raised its stake in Biogen by 1.2% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock worth $866,000 after acquiring an additional 57 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted third-quarter earnings of $2.62 per share, well above analyst expectations of roughly $1.99–$2.06, while revenue rose 10.6% year over year to $2.80 billion, also exceeding estimates. Biogen third-quarter earnings report
• Positive Sentiment: The newer growth portfolio continued to offset pressure on older multiple sclerosis products, with revenue increasing 49% to $1.26 billion. Rare-disease revenue rose 27% to $676 million, helped in part by the first full quarter of products acquired through Apellis. Biogen Q3 revenue and earnings update
• Positive Sentiment: Biogen raised the lower end of its 2026 adjusted EPS guidance to $12.20, producing a new range of $12.20 to $13.00. Needham and Baird subsequently raised their price targets to $290 and assigned bullish “buy” and “outperform” ratings, respectively. Analyst forecasts for Biogen
• Neutral Sentiment: Biogen plans to present additional Alzheimer’s disease data at CTAD 2026, including long-term CELIA study data for diranersen and extended real-world and clinical evidence for lecanemab. The presentations could provide future pipeline catalysts, but the data will not affect near-term earnings. Biogen CTAD 2026 announcement
• Negative Sentiment: Despite the adjusted-profit beat, Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, compared with a profit of $466.5 million a year earlier. The loss primarily reflected transaction-related expenses, including $284 million of acquired research and development costs tied largely to the RayThera acquisition. Biogen GAAP loss report
• Negative Sentiment: Barclays raised its price target to $230 but retained an “equal weight” rating, leaving its target below the current trading level. Unusually heavy put-option activity also indicated increased near-term hedging or bearish speculation. Barclays Biogen rating

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company's portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer's disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.